Research ArticleOriginal Article
Open Access

Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate

Mohammed M. Al-Bogami, Mohammed A. Alkhorayef, Jonas Bystrom, Olufunso A. Akanle, Nasra K. Al-Adhoubi, Ali S. Jawad and Rizgar A. Mageed
Saudi Medical Journal November 2015, 36 (11) 1305-1311; DOI: https://doi.org/10.15537/smj.2015.11.12731

References

  1. ↵
    1. Sandhu SK,
    2. Hampson G
    (2011) The pathogenesis, diagnosis, investigation and management of osteoporosis. J Clin Pathol 64:1042–1050.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Harvey N,
    2. Dennison E,
    3. Cooper C
    (2014) Osteoporosis: a lifecourse approach. J Bone Miner Res 29:1917–1925.
    OpenUrl
  3. ↵
    1. Cauley JA,
    2. Chalhoub D,
    3. Kassem AM,
    4. Fuleihan Gel-H
    (2014) Geographic and ethnic disparities in osteoporotic fractures. Nat Rev Endocrinol 10:338–351.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Giger EV,
    2. Castagner B,
    3. Leroux JC
    (2013) Biomedical applications of bisphosphonates. J Control Release 167:175–188.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Russell RG
    (2011) Bisphosphonates: the first 40 years. Bone 49:2–19.
    OpenUrlCrossRefPubMedWeb of Science
    1. Watts NB,
    2. Diab DL
    (2010) Long-Term Use of Bisphosphonates in Osteoporosis. J Clin Endocrinol Metab 95:1555–1565.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Kanis JA,
    2. Reginster JY,
    3. Kaufman JM,
    4. Ringe JD,
    5. Adachi JD,
    6. Hiligsmann M,
    7. et al.
    (2012) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int 23:213–221.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Lee S,
    2. Glendenning P,
    3. Inderjeeth CA
    (2011) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 22:741–753.
    OpenUrlPubMed
  9. ↵
    1. Bauer DC,
    2. Schwartz A,
    3. Palermo L,
    4. Cauley J,
    5. Hochberg M,
    6. Santora A,
    7. et al.
    (2014) Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med 174:1126–1134.
    OpenUrl
  10. ↵
    1. Boonen S,
    2. Reginster JY,
    3. Kaufman JM,
    4. Lippuner K,
    5. Zanchetta J,
    6. Langdahl B,
    7. et al.
    (2012) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 367:1714–1723.
    OpenUrlCrossRefPubMedWeb of Science
    1. Miller PD,
    2. Recker RR,
    3. Harris S,
    4. Silverman S,
    5. Felsenberg D,
    6. Reginster J,
    7. et al.
    (2014) Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporos Int 25:349–357.
    OpenUrl
  12. ↵
    1. Donaldson MG,
    2. Palermo L,
    3. Ensrud KE,
    4. Hochberg MC,
    5. Schousboe JT,
    6. Cummings SR
    (2012) Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial. J Bone Miner Res 27:1804–1810.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Levis S,
    2. Theodore G
    (2012) Summary of AHRQ’s comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. J Manag Care Pharm 18(4 Suppl B):S1–S15.
    OpenUrlPubMed
  14. ↵
    1. McClung MR,
    2. Zanchetta JR,
    3. Racewicz A,
    4. Roux C,
    5. Benhamou CL,
    6. Man Z,
    7. et al.
    (2013) Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporos Int 24:293–299.
    OpenUrl
    1. Merck Sharp and Dohme Limited
    (2010) Fosamax: Summary of Product Characteristics, Available from:http://www.medicines.org.uk/emc/medicine/1175/SPC/Fosamax/. cited 22 October 2012.
    1. Bianchi G,
    2. Czerwinski E,
    3. Kenwright A,
    4. Burdeska A,
    5. Recker RR,
    6. Felsenberg D
    (2012) Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporos Int 23:1769–1778.
    OpenUrlPubMed
    1. Hongo M,
    2. Miyakoshi N,
    3. Kasukawa Y,
    4. Ishikawa Y,
    5. Shimada Y
    (2015) Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial. J Bone Miner Metab 33:432–439.
    OpenUrl
  18. ↵
    1. Brown JP,
    2. Roux C,
    3. Ho PR,
    4. Bolognese MA,
    5. Hall J,
    6. Bone HG,
    7. et al.
    (2014) Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporos Int 25:1953–1961.
    OpenUrl
  19. ↵
    1. Modi A,
    2. Siris ES,
    3. Steve Fan CP,
    4. Sajjan S
    (2015) Gastrointestinal events among patients initiating osteoporosis therapy: a retrospective administrative claims database analysis. Clin Ther 37:1228–1234.
    OpenUrl
    1. McClung MR,
    2. Grauer A,
    3. Boonen S,
    4. Bolognese MA,
    5. Brown JP,
    6. Diez-Perez A,
    7. et al.
    (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Hadji P,
    2. Gamerdinger D,
    3. Spieler W,
    4. Kann PH,
    5. Loeffler H,
    6. Articus K,
    7. et al.
    (2012) Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Osteoporos Int 23:625–633.
    OpenUrlPubMed
  22. ↵
    1. Jiang E,
    2. Wang Z,
    3. Meng Q,
    4. Li S,
    5. Wang F,
    6. Shao G,
    7. et al.
    (2012) Study on bone density at various skeletal sites for the diagnosis of primary osteoporosis. Cell Biochem Biophys 64:1–3.
    OpenUrlPubMed
  23. ↵
    1. Hadji P,
    2. Claus V,
    3. Ziller V,
    4. Intorcia M,
    5. Kostev K,
    6. Steinle T
    (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223–231.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Li L,
    2. Roddam A,
    3. Gitlin M,
    4. Taylor A,
    5. Shepherd S,
    6. Shearer A,
    7. et al.
    (2012) Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database. Menopause 19:33–40.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Pereira RM,
    2. Carvalho JF,
    3. Paula AP,
    4. Zerbini C,
    5. Domiciano DS,
    6. Gonçalves H,
    7. et al.
    (2012) Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol 52:580–593, English, Portuguese.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Rietbrock S,
    2. Olson M,
    3. van Staa TP
    (2009) The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM 102:35–42.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Reid R,
    2. Gamble GD,
    3. Mesenbrink P,
    4. Lakatos P,
    5. Black DM
    (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95:4380–4387.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Catalano A,
    2. Morabito N,
    3. Atteritano M,
    4. Basile G,
    5. Cucinotta D,
    6. Lasco A
    (2012) Vitamin D Reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis. Calcif Tissue Int 90:279–285.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Diel IJ,
    2. Weide R,
    3. Köppler H,
    4. Antràs L,
    5. Smith M,
    6. Green J,
    7. et al.
    (2009) Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. Support Care Cancer 17:719–725.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Unnanuntana A,
    2. Gladnick BP,
    3. Donnelly E,
    4. Lane JM
    (2010) The assessment of fracture risk. J Bone Joint Surg Am 92:743–753.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section